Advertisement Eyenovia, Senju sign license and development agreement for ophthalmic therapeutics - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Eyenovia, Senju sign license and development agreement for ophthalmic therapeutics

US-based pharmaceutical firm Eyenovia has signed an exclusive license and development agreement with Japanese firm Senju Pharmaceutical, to develop ophthalmic therapeutics based on microdrops technology.

As part of the deal, Senju acquires the exclusive rights to develop and commercialize microdosed therapeutics in Japan and the rest of Asia.

Apart from the licensing deal, Senju is also joining the Series A investment syndicate alongside Private Medical Equity, Eshelman Ventures and Mario Family Partners, while the Japanese firm will also assume responsibility for all research and development (R&D) activities in Asia.

A clinical-stage technology has been developed by Eyenovia for microdosing of ophthalmic medications which can improve bioavailability, efficacy and safety of many existing drugs without the need for chemical reformulation.

For superior treatment approaches in eye care, the Eyenovia ‘smart’ piezoelectric delivery system provides high-precision, high-adhesion ocular surface coating along with electronic compliance monitoring and mobile digital eye health functions.

Eyenovia chairman Fred Eshelman said: "This is a great partnership for Eyenovia and we are pleased that Senju, one of Japan’s premier specialty pharmaceutical companies, has recognized the potential of Eyenovia’s transformative technology and has committed to spearheading the development of the Asia market."